Regeneron's double antibody cocktail therapy prevents new coronavirus COVID-19 infection and enters Phase III study phase

Regeneron Pharmaceuticals announced the start of Phase III clinical studies to evaluate the use of dual antibody cocktail therapy REGN-COV2 forpreventionspecifically for close contact with the hivetheinfectedin patients with the new coronavirusCOVID-19Photo Source:REGN-COV2 is a mixture of REGN10933 and REGN10987 neutralizing antibodies, both of which bind in a non-competitive manner to receptors of the SARS-CoV-2 virus stingproteinThe evaluation of REGN-COV2 treatment of COVID-19 inpatients and non-inpatients has also entered the Phase II/III study phaseThe clinical progress of REGN-COV2 is based on safety results in 30 in-patient and non-inpatient COVID-19 patients studied by the Independent Data Monitoring Boardlast month, Regeneron began conducting the first placebo-controlled study to study REGN-COV2 and treat COVID-19 infectionThe clinical program will consist of four independent study populations, including in-patient and non-hospitalized PATIENTs with COVID-19, and uninfected populations with high risk of exposure or close contact with PATIENTs with COVID-19said a joint prevention study with the U.SNational Institute of Allergy and Infectious Diseases is expected to recruit 2,000 patients in the U.SMeanwhile, two other trials will recruit 1,850 hospitalizations and 1,050 non-hospitalized patients in the United States, Brazil, Mexico and Chile, with preliminary data expected later this summer